{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:13:29Z","timestamp":1791576809025,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T00:00:00Z","timestamp":1371513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00228-013-1551-3","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T03:17:02Z","timestamp":1371439022000},"page":"1901-1907","source":"Crossref","is-referenced-by-count":16,"title":["An acenocoumarol dose algorithm based on a South-Eastern European population"],"prefix":"10.1007","volume":"69","author":[{"given":"Tudor Radu","family":"Pop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015etefan Cristian","family":"Vesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Pavel","family":"Trifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin","family":"Cri\u015fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Dana","family":"Buzoianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,18]]},"reference":[{"issue":"5","key":"1551_CR1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.clpt.2004.01.007","volume":"75","author":"H Takahashi","year":"2004","unstructured":"Takahashi H, Wilkinson GR, Padrini R, Echizen H (2004) CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 75(5):376\u2013380. doi: 10.1016\/j.clpt.2004.01.007","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1551_CR2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41(2):89\u2013295. doi: 10.1080\/03602530902843483","journal-title":"Drug Metab Rev"},{"issue":"2 Suppl","key":"1551_CR3","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141[2 Suppl]:e44S\u2013e88S. doi: 10.1378\/chest.11-2292","journal-title":"Chest"},{"issue":"12","key":"1551_CR4","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1111\/j.1582-4934.2012.01606.x","volume":"16","author":"AD Buzoianu","year":"2012","unstructured":"Buzoianu AD, Trifa AP, Mure\u015fanu DF, Cri\u015fan S (2012) Analysis of CYP2C9*2, CYP2C9*3 and VKORC1\u20131639 G\u2009>\u2009A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med 16(12):2919\u20132924. doi: 10.1111\/j.1582-4934.2012.01606.x","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1551_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2006.10.021","volume":"120","author":"T Yin","year":"2007","unstructured":"Yin T, Miyata T (2007) Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1\u2014rationale and perspectives. Thrombosis Res 120(1):1\u201310. doi: 10.1016\/j.thromres.2006.10.021","journal-title":"Thrombosis Res"},{"key":"1551_CR6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00008571-199402000-00005","volume":"4","author":"AE Rettie","year":"1994","unstructured":"Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics 4:39\u201342","journal-title":"Pharmacogenetics"},{"key":"1551_CR7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00008571-199706000-00005","volume":"7","author":"CL Crespi","year":"1997","unstructured":"Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203\u2013210","journal-title":"Pharmacogenetics"},{"issue":"1","key":"1551_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2006.04.006","volume":"80","author":"T Schalekamp","year":"2006","unstructured":"Schalekamp T, Brass\u00e9 BP, Roijers JFM, Chahid Y, van Geest-Daalderop JHH et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80(1):13\u201322. doi: 10.1016\/j.clpt.2006.04.006","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"1551_CR9","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","volume":"287","author":"MK Higashi","year":"2002","unstructured":"Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690\u20131698. doi: 10.1001\/jama.287.13.1690","journal-title":"JAMA"},{"issue":"1","key":"1551_CR10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00008571-200401000-00003","volume":"14","author":"LE Visser","year":"2004","unstructured":"Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG et al (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14(1):27\u201333","journal-title":"Pharmacogenetics"},{"issue":"3","key":"1551_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-009-0768-7","volume":"66","author":"J Cadamuro","year":"2010","unstructured":"Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M et al (2010) Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 66(3):253\u2013260. doi: 10.1007\/s00228-009-0768-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1551_CR12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.tibs.2004.04.004","volume":"29","author":"L Goodstadt","year":"2004","unstructured":"Goodstadt L, Ponting CP (2004) Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci 29(6):289\u2013292. doi: 10.1016\/j.tibs.2004.04.004","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"1551_CR13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/01.fpc.0000184955.08453.a8","volume":"16","author":"H Takahashi","year":"2006","unstructured":"Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2):101\u2013110. doi: 10.1097\/01.fpc.0000184955.08453.a8","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"1551_CR14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2141.2006.06007.x","volume":"133","author":"R Montes","year":"2006","unstructured":"Montes R, Ruiz de Gaona E, Mart\u00ednez-Gonz\u00e1lez MA, Alberca I, Hermida J (2006) The c.-1639G\u2009>\u2009A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 133(2):183\u2013187. doi: 10.1111\/j.1365-2141.2006.06007.x","journal-title":"Br J Haematol"},{"issue":"2","key":"1551_CR15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-126-2-199701150-00006","volume":"126","author":"L Harrison","year":"1997","unstructured":"Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126(2):133\u2013136. doi: 10.7326\/0003-4819-126-2-199701150-00006","journal-title":"Ann Intern Med"},{"issue":"9","key":"1551_CR16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-138-9-200305060-00007","volume":"138","author":"MJ Kovacs","year":"2003","unstructured":"Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J et al (2003) Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 138(9):714\u2013719","journal-title":"Ann Intern Med"},{"issue":"6","key":"1551_CR17","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1160\/TH04-02-0083","volume":"91","author":"HV Joffe","year":"2004","unstructured":"Joffe HV, Xu R, Johnson FB, Longtine J, Kucher N, Goldhaber SZ (2004) Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 91(6):1123\u20131128. doi: 10.1160\/TH04-02-0083","journal-title":"Thromb Haemost"},{"issue":"2","key":"1551_CR18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00228-007-0424-z","volume":"64","author":"J Brockm\u00f6ller","year":"2008","unstructured":"Brockm\u00f6ller J, Tzvetkov MT (2008) Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 64(2):133\u2013157. doi: 10.1007\/s00228-007-0424-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"1551_CR19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00003088-200847090-00002","volume":"47","author":"S Stehle","year":"2008","unstructured":"Stehle S, Kirchheiner J, Lazar A, Fuhr U (2008) Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 47(9):565\u2013594. doi: 10.2165\/00003088-200847090-00002","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1551_CR20","doi-asserted-by":"crossref","first-page":"e41360","DOI":"10.1371\/journal.pone.0041360","volume":"7","author":"AM Borobia","year":"2012","unstructured":"Borobia AM, Lubomirov R, Ram\u00edrez E, Lorenzo A, Campos A, Mu\u00f1oz-Romo R et al (2012) An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in spanish patients with thromboembolic disease. PLoS One 7(7):e41360. doi: 10.1371\/journal.pone.0041360","journal-title":"PLoS One"},{"issue":"6","key":"1551_CR21","doi-asserted-by":"crossref","first-page":"e11210","DOI":"10.1371\/journal.pone.0011210","volume":"5","author":"Z Verde","year":"2010","unstructured":"Verde Z, Ruiz JR, Santiago C, Valle B, Bandr\u00e9s F et al (2010) A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 5(6):e11210. doi: 10.1371\/journal.pone.0011210","journal-title":"PLoS One"},{"issue":"15","key":"1551_CR22","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/eurheartj\/ehr116","volume":"32","author":"RMF Schie van","year":"2011","unstructured":"van Schie RMF, Wessels JAM, le Cessie S, de Boer A, Schalekamp T, van der Meer FJM et al (2011) Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 32(15):1909\u20131917. doi: 10.1093\/eurheartj\/ehr116","journal-title":"Eur Heart J"},{"issue":"3","key":"1551_CR23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2125.1999.00012.x","volume":"48","author":"AS Aynacioglu","year":"1999","unstructured":"Aynacioglu AS, Brockm\u00f6ller J, Bauer S, Sachse C, G\u00fczelbey P, Ongen Z et al (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48(3):409\u2013415. doi: 10.1046\/j.1365-2125.1999.00012.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1551_CR24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/sj.clpt.6100453","volume":"84","author":"MS Wen","year":"2008","unstructured":"Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH et al (2008) Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 84(1):83\u201389. doi: 10.1038\/sj.clpt.6100453","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1551_CR25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2125.1984.tb02494.x","volume":"18","author":"M Arboix","year":"1984","unstructured":"Arboix M, Laporte JR, Frati ME, Rutllan M (1984) Effect of age and sex on acenocoumarol requirements. Br J Clin Pharmacol 18(4):475\u2013479","journal-title":"Br J Clin Pharmacol"},{"key":"1551_CR26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0163-7258(88)90115-5","volume":"36","author":"CM Loi","year":"1988","unstructured":"Loi CM, Vestal RE (1988) Drug metabolism in the elderly. Pharmacol Ther 36:131\u2013149. doi: 10.1016\/0163-7258(88)90115-5","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1551_CR27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2710.1998.00164.x","volume":"23","author":"E Tanaka","year":"1998","unstructured":"Tanaka E (1998) In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 23(4):247\u2013255","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"1551_CR28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","volume":"4","author":"AW Dreisbach","year":"2008","unstructured":"Dreisbach AW, Lertora JJ (2008) The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 4(8):1065\u20131074. doi: 10.1517\/17425255.4.8.1065","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1551_CR29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2125.1977.tb00786.x","volume":"4","author":"S Husted","year":"1977","unstructured":"Husted S, Andreasen F (1977) The influence of age on the response to anticoagulants. Br J Clin Pharmacol 4:559\u2013565","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1551_CR30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2141.2011.08633.x","volume":"153","author":"M Teichert","year":"2011","unstructured":"Teichert M, van Noord C, Uitterlinden AG, Hofman A, Buhre PN, De Smet PA et al (2011) Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol 153(3):379\u2013385. doi: 10.1111\/j.1365-2141.2011.08633.x","journal-title":"Br J Haematol"},{"issue":"10","key":"1551_CR31","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3109\/00365529709011215","volume":"32","author":"EM Vreeburg","year":"1997","unstructured":"Vreeburg EM, De Vlaam-Schluter GM, Trienekens PH, Snel P, Tytgat GN (1997) Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scand J Gastroenterol 32(10):991\u2013994. doi: 10.3109\/00365529709011215","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"1551_CR32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1365-2125.1997.00600.x","volume":"44","author":"JN Hoon de","year":"1997","unstructured":"de Hoon JN, Thijssen HH, Beysens AJ, Van Bortel LM (1997) No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 44(4):399\u2013401. doi: 10.1046\/j.1365-2125.1997.00600.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1551_CR33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1515\/dmdi-2012-0024","volume":"27","author":"RM Schie van","year":"2012","unstructured":"van Schie RM, Verhoef TI, Boejharat SB, Schalekamp T, Wessels JA, le Cessie S et al (2012) Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug Metabol Drug Interact 27(4):229\u2013234. doi: 10.1515\/dmdi-2012-0024","journal-title":"Drug Metabol Drug Interact"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1551-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1551-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T16:59:40Z","timestamp":1563209980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1551-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,18]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1551-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,18]]}}}